We previously described in the CCL39 hamster ®broblast cell line the inhibition of DNA synthesis reinitiation by agents that elevate cyclic AMP. Here, we show that 8Br-cAMP strongly blocks both the growth factor-induced increase in cyclin D1 protein expression and decrease in p27 KIP1 protein levels, leaving untouched the levels of cyclin D3, cdk2 and cdk4. To assess the role of cyclin D1 in the cAMP-mediated inhibition of DNA synthesis, we overexpressed the cyclin D1 gene in CCL39 and analysed the cAMP response in stable transfectants. We showed that the kinase activities associated to G 1 cyclincdk complexes are signi®cantly more resistant to cAMP in cyclin D1 transfectants than in their normal counterparts, although the serum-induced p27 KIP1 disparition is still cAMP sensitive in cyclin D1 overexpressors. Interestingly, the mitogen-induced DNA synthesis reinitiation is also much less inhibited by cAMP in cyclin D1 transfectants than in control cells. These data clearly establish that the cAMP-inducible blockade of the G 1 phase of the cell cycle can be partially alleviated by overexpression of cyclin D1 in hamster ®broblasts, thus strongly suggesting that cyclin D1 protein is one of the major targets for cAMP inhibitory action in ®broblasts.
Introduction
Cyclic AMP has been described as a mediator of numerous physiological processes. Large increases in cAMP concentration inside the cell are generally growth inhibitory for most cell lines of mesenchymental origin. Accordingly, we previously published (Magnaldo et al., 1989) that any sustained increase in cAMP level was detrimental for DNA synthesis reinitiation in the hamster ®broblast cell line CCL39. But the exact mechanism by which cAMP exerts its inhibitory action remains largely unknown or somewhat controversial. We subsequently showed that activation of the p42/p44 MAP kinase pathway (ERK pathway) was an obligatory step to trigger cell mitogenicity (PageÁ s et al., 1993 (PageÁ s et al., , 1994 . This signalling cascade was indeed a potential target for cAMP inhibition. However, we now show that in various ®broblastic cell lines, the inhibition of cAMP on growth factor-induced activation of p42/ p44 MAP kinases was very transient and could not account for the growth inhibitory action of cAMP (Kahan et al., 1992; McKenzie and Pouyssegur, 1996) . Therefore, other cAMP targets should be considered and we looked for target(s) downstream of the p42/p44 MAP kinase pathway. Progression through the G 1 phase of the cell cycle is orchestrated by complexes containing a G 1 -speci®c cyclin and a G 1 -speci®c cyclindependent kinase (Cdk): among those, cyclin D family members are found associated with either cdk4 or cdk6 in early G 1 phase, and cyclin E with cdk2 in late G 1 (see for reviews Draetta, 1994; Grana and Reddy, 1995; Reed et al., 1994; Sherr, 1993) . Activity of these complexes can be inhibited by the presence of a cyclin kinase inhibitor (CKI), which belongs to an expanding new family of mammalian cell cycle modulators comprising so far p21 Cip1 , p27 KIP1 , p57 KIP2 in one subfamily, and p16
INK4A
, p15 INK4B , p18 INK4C and p19 INK4D in the other (Lees, 1995; Sherr and Roberts, 1995 for reviews), with p27 KIP1 being recently involved in the inhibitory process induced by cAMP in macrophages . At the G 1 -4S phase transition, the tumor suppressor pRb, product of the retinoblastoma gene, is inactivated by hyper-phosphorylation, thus leaving free the transcription factors E2Fs to activate E2 site-containing gene promoters (Dyson, 1994 for a review). The inactivation of pRb has recently been shown to be performed in vivo by a series of various G 1 cyclin-kinase complexes (Horton et al., 1995; Suzuki-Takahashi et al., 1995) . Not only pRb regulates cyclin D1 expression (Muller et al., 1994) , but a strict relationship between cyclin D1 and pRb has been established: if pRb function is de®cient, the cyclin D1 requirement in the G 1 -4S progression becomes dispensable (Bates et al., 1994; Lukas et al., 1994a Lukas et al., , 1995a .
Here, we addressed the question of which, if any, cell cycle regulatory protein was targeted by cAMP. A previous report from our laboratory (Magnaldo et al., 1989) targeted the cAMP growth inhibition as taking place in the early G 0 /G 1 phase, more precisely during the ®rst 6 h of growth factor addition. Interestingly, addition of cAMP agonists for the ®rst 4 h following growth factor stimulation delayed S phase entry by roughly the same time period (Magnaldo et al., 1989) . Thus, the cell cycle regulatory protein cyclin D1, that has been described as an essential component of an early G 1 checkpoint and as governing cell cycle exit (Zwijsen et al., 1996) , appeared to be a good candidate. Indeed, cyclin D1 overexpression deregulated cell growth of normal cells (Han et al., 1995; Jiang et al., 1993; Quelle et al., 1993; Resnitzky et al., 1994) whereas antisense to this cyclin inhibited growth of transformed cells (Zhou et al., 1995) . Here, we used the 8Br-cAMP, a non-hydrolysable but diusible cAMP analog, and found that cyclin D1 protein expression was strongly repressed by such a sustained increase in cAMP level. In order to establish whether or not cyclin D1 was the major protein targeted by the inhibitory pathway triggered by cAMP, we then ectopically expressed the human cyclin D1 gene in the non-transformed hamster ®broblast cell line CCL39 and analysed the resulting sensitivity to cAMP of G 1 cyclin-cdk complexes and of DNA synthesis reinitiation.
Results

cAMP eect on kinetics of expression of various cell cycle regulatory proteins in hamster ®broblasts
We ®rst examined the eect of a pre-incubation with 1 mM 8Br-cAMP on the serum-induced protein expression of dierent cell cycle regulatory proteins in the hamster ®broblast line CCL39. Figure 1 shows a series of immunoblots loaded with CCL39 cell lysates and decorated with speci®c antibodies against either cyclin D1, cyclin D3, cdk2, cdk4, p27 KIP1 or pRb. Upper panel of Figure 1 indicates that cyclin D1 protein is not present (or barely detectable) in quiescent cells but its expression could be detected as soon as 6 h after serum stimulation, with the protein level increasing between 6 and 20 h. Interestingly, 1 mM 8Br-cAMP strongly blocked such an expression over all this period of time. Like in other studies (Lukas et al., 1995a; Matsushime et al., 1994) , the appearance of a slow migrating form of cyclin D1 correlates with the strongly induced major cyclin D1 band. Its identity is unknown but cannot correspond to either the cyclin D2 or D3 isoforms.
Besides cyclin D1 (Baldin et al., 1993; Lukas et al., 1994b) , both cyclin D2 and cyclin D3 have also been involved in controlling the G 1 phase (Ando et al., 1993; Kiess et al., 1995; Kiyokawa et al., 1994; Lukas et al., 1995b; Skapek et al., 1995) with cyclin D3 mostly implicated in cell dierentiation (Kiess et al., 1995; Kiyokawa et al., 1994; Skapek et al., 1995) , a process inhibited by cyclin D1 (Skapek et al., 1995) . We thus checked for their presence into CCL39 cells. Upper panel of Figure 1 also shows that the cyclin D3 isoform was already present in G 0 -arrested cells but its expression was only slightly induced by growth factors Eect of 8Br-cAMP on the expression levels of various cell cycle regulatory proteins in hamster ®broblasts. G 0 -arrested CCL39 cells (0) were activated with 10% FCS with (+) or without (7) for the indicated times before cell lysis. All protein lysates (75 mg) were separated by 10% SDS ± PAGE (except 7.5% for pRb), blotted and immunodecorated with speci®c antibodies as indicated cAMP inhibits cell growth via cyclin D1 G L'Allemain et al and resistant to the 8Br-cAMP treatment, thus excluding its putative role in cAMP inhibition. Use of four dierent antibodies, monoclonal and polyclonal, did not allow us to detect cyclin D2 isoform in CCL39 cells (data not shown), a situation encountered in ®broblasts as well as in other cell types . On the lower panel of Figure 1 , we analysed the hyper-phosphorylation state of pRb which is, in late G 1 phase, a landmark for normal cells passing the restriction point and entering S phase (Grana and Reddy, 1995 for a review). Not less than 10 h of serum addition are necessary to obtain a signi®cant portion of the slow migrating (i.e. hyper-phosphorylated) form of pRb. This result is in agreement with the appearance of cyclin D1 at 6 h since reports indicate that cyclin D1, in association with cdk4, could in part be responsible for in vivo hyper-phosphorylation of pRb (Horton et al., 1995; Kato et al., 1993; Suzuki-Takahashi et al., 1995) . After serum addition, the ratio between hypervs hypo-phosphorylated pRb, as determined by densitometric scanning, reaches 50% at 10 h. Interestingly, 1 mM 8Br-cAMP almost completely blocks the appearance of the hyper-phosphorylated inactive form of pRb.
The speci®city of cAMP action was then assessed by analysing the levels of cdk4 or cdk2, two proteins whose activity is required for G 0 /G 1 -4S phase progression. The same cAMP increasing treatment did not induce a signi®cant inhibition of the protein expression of cdk2 or cdk4, a result indicative of the rather speci®c cAMP action since cdk4 protein expression was already described as being aected by TGFb, an inhibitor of DNA synthesis reinitiation in epithelial cells .
Finally, because variations of p27 KIP1 levels were described as mediating the cAMP inhibition of DNA synthesis in macrophages , the same lysates were also checked for any variation of p27 KIP1 . We found that the decrease in p27 KIP1 levels observed after serum addition (40% at 6 h, 50% at 10 h, 60% at 20 h as assessed by densitometry analysis) is totally blocked by 8Br-cAMP addition. Evenmore, the same analysis reveals a slight increase of 20 to 30% in cells treated by 8Br-cAMP as supposed to the untreated cells.
Kinetics of S phase entry in cyclin D1 transfectants
To examine precisely the role of the cyclin D1 in the inhibitory action of cAMP, transfection experiments of the human cyclin D1 cDNA were then conducted both in the hamster ®broblast line CCL39 and in its mutant derivative PS120, which lacks a functional Na + /H + exchange protein (PouysseÂ gur et al., 1984) . Thus, the Na + /H + antiporter activity was used as the selective marker in co-transfection experiments (see Materials and methods section). From independently transfected populations of hamster ®broblasts, two clones exhibiting dierent levels of cyclin D1 were isolated, and then analysed for their kinetics of S phase entry. Among 27 colonies, 39-D1 and PS-D1 clones, representative of each transfected population (respectively CCL39 and PS120), were chosen for expressing dierent levels of cyclin D1 in resting cells. An anti-cyclin D1 immunoblot (Figure 2 , inset) made with lysates from resting cells showed that both D1 transfectants (39-D1, PS-D1) exhibited much higher levels of cyclin D1 (respectively, ®ve and 12 times more as assessed by densitometry) than their control counterparts transfected with the empty vector (39-C, PS-C). Interestingly, the PS-D1 clone was expressing 3 ± 4 times more cyclin D1 than 39-D1. Main panel of Figure 2 shows the timing of entry into S phase exhibited by these four cell lines after serum deprivation for 24 h followed by reactivation by growth factors. Thymidine incorporation in resting cells was very low and essentially identical both in control and D1-transfected clones, indicating that the cyclin D1 transfectants were not relaxed for growth factor requirement. Data in Figure  2 also shows that the DNA synthesis induced by serum was much higher in D1 transfectants than in control cells, suggesting that cyclin D1 is rate-limiting for DNA synthesis in hamster ®broblasts. From the same thymidine-pulse experiment, the cyclin D1 transfectants appear to enter S phase sooner than their normal counterparts (see Discussion).
cAMP eect on cyclin D1 protein expression in cyclin D1 transfectants Figure 3 shows the cAMP eect in D1 transfectants vs their normal counterparts for cyclin D1 protein expression either from whole cell lysates (Figure 3a) or from anti-cdk4 immunoprecipitates (Figure 3b ). Whereas the serum-induced cyclin D1 expression is severely inhibited by 1 mM 8Br-cAMP in the control transfectants (39-C and PS-C), the cyclin D1 protein levels are unchanged in the 39-D1 and PS-D1 clones ( Figure 3a ). This result indicates that cyclin D1 transfectants are no longer sensitive to cAMP in terms of cyclin D1 expression, an expected result with the cyclin D1 cDNA placed under the control of the heterologous CMV promoter. Although no cyclin D1-cdk4 association was detected in quiescent cells, much more cyclin D1-cdk4 complex was present in D1 transfectants than in control transfectants, suggesting that cyclin D1 was rate-limiting for complex formation. We thus identi®ed by co-immunoprecipitation the cdk protein that mainly associated with cyclin D1 in hamster ®broblasts as being cdk4. Interestingly, such an association was resistant to 1 mM 8Br-cAMP treatment in both the cyclin D1 transfectants and the control transfectants, thus suggesting that the mechanism of complex formation was not targeted by cAMP.
cAMP eect on p27 KIP1 protein expression in D1 transfectants
Two dierent regulatory mechanisms can explain the growth factor-induced variations in p27 KIP1 levels: activation of its degradation and inhibition at the translational level of its synthesis (Agrawal et al., 1996; Hengst and Reed, 1996) . Whatever the mechanism of regulation involved in the stabilization of p27 KIP1 levels by cAMP, we compared the sensitivity of p27 KIP1 to cAMP in the four cell transfectants 39-C, PS-C, 39-D1 and PS-D1. Figure 4 shows that the resting level of p27 KIP1 protein is roughly the same in these four cell lines. This result suggests that cyclin D1 overexpression does not in¯uence the steady-state level of p27 KIP1 in G 0 state. The same ®gure also demonstrates that serum addition elicits the p27 KIP1 disappearance in the four cell lines. More interestingly, treatment with 1 mM 8Br-cAMP appears to prevent the serum-induced reduction in p27 KIP1 protein levels both in the control transfectants and in the cyclin D1 transfectants. Thus, in D1 transfectants, the variations in p27 KIP1 levels stay sensitive to cAMP (Figure 4 ) in spite of the constitutive levels of cyclin D1 protein and high levels of cyclin D1/cdk4 activity (see next section). These data indicate that cyclin D1 can be induced without a prior reduction in the p27 KIP1 levels, a result suggesting that the growth factor-induced variations in cyclin D1 and p27 KIP1 levels are regulated independently.
Eect of cAMP on FCS-induced cyclin-associated kinase activities in D1 transfectants
To analyse more precisely the mechanism of inhibitory action of cAMP, we then compared in cyclin D1 transfectants vs control cells the levels of cyclin D1-associated kinase activity. After an immunoprecipitation with anti-cyclin D1 antibodies, cell lysates were tested for their capacity to phosphorylate the cyc D1¨-
Figure 3 Eect of 8Br-cAMP on serum-induced cyclin D1 protein expression and cyclin D1-CDK4 complex formation in parental vs cyclin D1 expressing cells. Quiescent 39-C, 39-D1, PS-C and PS-D1 cells were (+) or not (7) stimulated with serum for 12 h in the presence (+) or in the absence (7) ] into pRb-GST was undetectable in control cells and barely detectable in D1 transfectants, whereas 12 h of serum addition triggered high D1 kinase activity in PS-D1 cells (Figure 5 ), the extent of which appearing as a function of the expression level of cyclin D1 protein (compare PS-D1 to 39-D1). Interestingly, 1 mM 8Br-cAMP treatment induced very low inhibition on cyclin D1-associated activity in D1 transfectants (25% in 39-D1 and 12% in PS-D1 as compared to 95% and 90% in their corresponding control transfectants). These results indicated that the cyclin D1-associated kinase activity induced by serum in the cyclin D1 transfectants is almost fully resistant to the cAMP treatment.
Because cyclin D1 is also known to form complexes with cdk2 and cdk6, and cdk4 to associate with cyclins D2 and D3 (Sherr and Roberts, 1995 for review), we tested in D1 transfectants the sensitivity of cdk4 activity to the same 8Br-cAMP treatment. Figure 6a showed that kinase activities exhibited by anti-cdk4 immunoprecipitates from D1 transfectants stimulated 12 h with serum, are as resistant to cAMP (30% and 15% inhibition for respectively 39-D1 and PS-D1) as those exhibited by anti-cyclin D1 immunocomplexes issued from the same cells (compare with Figure 5 ).
Because cyclin E and cyclin D1 were recently described as being located on distinct although interdependent pathways (Ohtsubo et al., 1995; Resnitzky et al., 1995; Roussel et al., 1995) , we then asked, whether or not the enzymatic activity of cyclin E-cdk2 was sensitive to cAMP in the cyclin D1 transfectants. The results, shown in Figure 6b and c, unambiguously indicated that anti-cdk2 and anti-cyclin E immunocomplexes exhibited kinase activities much more elevated in D1 transfectants than in control transfectants. Interestingly, the enzymatic activities of both immunocomplexes were only slightly inhibited by 1 mM 8Br-cAMP in D1 transfectants (25 to 50% inhibition), as compared to control transfectants (80 to 100% inhibition).
cAMP eect in late G 1 phase of cyclin D1 transfectants Considering that mid-and late-G 1 cyclin dependent kinase activities were becoming resistant to cAMP inhibition in D1 transfectants (see Figures 5 and 6 ), we examined in late G 1 phase the phosphorylation state of pRb along with the cyclin A status in the four cell transfectants. Densitometry scanning from results shown in Figure 7a indicated that after 12 h of serum addition, the ratio between the hyper-and the hypophosphorylated forms of pRb is approximately 50 : 50 whatever the cell line. Interestingly, the serum-induced hyper-phosphorylation of pRb was fully blocked by 8Br-cAMP only in control transfectants. Truly, a signi®cant presence of hyper-phosphorylated pRb form is still detected in 8Br-cAMP-treated D1 transfectants, ä a b Figure 5 Eect of 8Br-cAMP on serum-induced cyclin D1 associated kinase activity in parental vs cyclin D1 expressing cells. Quiescent 39-C, 39-D1, PS-C and PS-D1 cells were (+) or not (7) stimulated with 10% FCS for 12 h in the presence (+) or in the absence (7) of 1 mM 8Br-cAMP. For each cell line, the kinase activity associated with anti-cyclin D1 immunocomplexes was determined. (a) shows an autoradiography of the gel; (b) presents the corresponding counts. The data presented are typical of at least three experiments Figure 6 Eect of 8Br-cAMP on serum-induced cyclin Eassociated, CDK2 and CDK4 kinase activities in parental and cyclin D1 expressing cells. Quiescent 39-C, 39-D1, PS-C and PS-D1 cells were (+) or not (7) stimulated with 10% FCS either for 12 h (a), or for 15 h (b and c), in the presence (+) or in the absence (7) of 1 mM 8Br-cAMP. Kinase activity of immunocomplexes generated with speci®c immunoprecipitating antibodies is shown on a for cdk4 antibodies, on c for cyclin E antibodies, on b for cdk2 antibodies. Parallel data were obtained in independent experiments. Note that the very slight inhibitory eect of cAMP which is observed in PS-D1 cells, is also detected with ®ve times less of PS-D1 cell lysates cAMP inhibits cell growth via cyclin D1 G L'Allemain et al result consistent with the phenotype of resistance to cAMP already exhibited in early and mid-G 1 phases by these cells. The anti-cyclin A immunoblot shown on Figure 7b clearly demonstrates that the expression levels of cyclin A is much more intense in D1 transfectants than in control cells after being challenged with serum. Noteworthy, addition of 1 mM 8Br-cAMP totally blocks cyclin A expression in control transfectants but has no eect in D1 transfectants. Thus, the early resistance to cAMP developed by cells overexpressing cyclin D1 is also detected in late G 1 for cyclin A expression. Considering the fact that cyclin A gene promoter carries E2F box, this result is in agreement with the presence of hyper-phosphorylated pRb in cAMP-treated D1 transfectants (Figure 7a ).
cAMP eect on DNA synthesis reinitiation in cyclin D1 transfectants
To analyse if the phenotype of resistance to cAMP would be also detected later for S phase entry as it was for G 1 phase progression, we assessed the DNA synthesis reinitiation in the same four cell lines by measuring the incorporation of radiolabelled thymidine for 1 h after 17 h of serum stimulation. Results shown in Figure 8 indicated that 1 mM 8Br-cAMP inhibited serum-induced DNA synthesis by respectively 75 and 80% in PS-C and 39-C control transfectants, but by only 30 and 60% in PS-D1 and 39-D1. These results indicated that the inhibitory action of cAMP on DNA synthesis can be partially alleviated by increasing cyclin D1 levels in hamster ®broblasts. Evenmore, every cyclin D1 expressing clone isolated during this study exhibited a lower sensitivity to cAMP than any of the control transfected clones isolated in parallel (data not shown). Thus, cyclin D1 expression truly constitutes one of the major steps targeted by cAMP in its inhibitory pathway on DNA synthesis.
Discussion
The growth inhibitory action of cAMP is known for more than 20 years (Pastan et al., 1975 ) and yet the mechanism by which this second messenger exerts its inhibitory action has remained unknown or highly controversial. Recently two interesting mechanisms have been proposed for its growth negative action. In the ®rst one, it was proposed that the p42/p44 MAPK cascade was the target of this inhibition in various ®broblast cell lines or in smooth muscle cells. Indeed, activation of PKA has been shown (Burgering and Bos, 1995, for a review) to inhibit Raf-1, the upstream kinase of the MAPK module. Although this action was satisfying in regard of the essential role played by the MAPK cascade in cell proliferation (PageÁ s et al., 1993), we showed that this inhbition was too transient in nature to account for the growth inhibitory action of cAMP (McKenzie and Pouyssegur, 1996) .
The second and perhaps more appealing mechanism was the demonstration that cAMP-mediated growth arrest is caused by an elevation of p27 Kip1 , a CK1 known to block cell cycle progression by targeting G 1 cyclin-dependent kinases. This action was reported to operate in cAMP-treated macrophages ). In the present study, we have shown that the concentration of cAMP (8Br-cAMP) known to antagonize cell cycle re-entry in response to growth factors has, in fact, a strong inhibitory action on cyclin D1 induction. This repression was similarly observed upon prostaglandin E1 treatment, a hormone which activates adenylyl cyclase, and reproduced in all cell types analysed; the immortalized hamster lung fibroblast line CCL39, secondary cultures of hamster or mouse ®broblasts, rat vascular smooth muscle cells (data not shown). Similar eects have been previously reported in other cell types (Cocks et al., 1992; Gagelin et al., 1994; Sewing et al., 1993; Vadiveloo et al., 1996; Winston et al., 1996) . As expected from such a cyclin D1 repression, the resulting cyclin D1-associated cdk4 and cdk2 activities, as well as pRb hyperphosphorylation, were blunted by 8Br-cAMP. We also noticed that 8Br-cAMP prevented the growth factor-mediated degradation of p27 Kip1 and even led to a slight increase (up to 30%) after a 24 h treatment (see Discussion later).
To test whether inhibition of cyclin D1 expression was the cause of this pleiotypic eect exerted by cAMP in mid and late G 1 phase, we generated cell lines constitutively expressing cyclin D1. These clones, in which cyclin D1 is now insensitive to cAMP action, are still capable of G 0 arrest upon serum-deprivation. Stably expressing cyclin D1 increased cdk4 and cdk2 activities, thus suggesting that cyclin D1 was ratelimiting. The apparent shortening of G 0 /G 1 phase seen in Figure 2 might simply re¯ect a better synchrony for cell cycle re-entry. Interestingly, in these cyclin D1-expressing cells, 8Br-cAMP failed to decrease significantly both cyclin D1-associated and cdk4 activities. However, kinasic activities in late G 1 such as cyclin Eassociated and total cdk2 activities were slightly reduced by 8Br-cAMP, but comparably much less than in control cells (30 ± 40% inhibition instead of 80% in control cells). As a consequence, the seruminduced pRb hyperphosphorylation was only slightly aected by cAMP in D1-expressing cells. Inhibition of DNA synthesis reinitiation, although still sensitive to 8Br-cAMP addition in cyclin D1-transfectants, was severely attenuated in particular in the high expressor PS-D1 (25% inhibition instead of 75% in control cells). These results clearly demonstrate that cyclin D1 is a critical target of cAMP-mediated growth inhibition, although not unique. The mechanism by which PKA antagonizes growth factor-mediated cyclin D1 induction is yet unknown. At least, this negative action is not at all mediated through an attenuation of the p42/ p44 MAPK activity, a signalling cascade crucial for cyclin D1 induction (Lavoie et al., 1996a) .
Another interesting point is the control of p27 Kip1 levels by cAMP. As originally reported in macrophages , agents increasing cAMP have a remarkable eect in preventing the mitogenicallyinduced p27 Kip1 down-regulation. This action certainly represents an attractive mechanism for cAMPmediated cell growth. However, we recently hypothesized (Rivard et al., 1996) that this inhibition of p27 Kip1 degradation merely re¯ects the consequence of a G1 block. Indeed this feature is not restricted to cAMP, but observed in various conditions leading to growth inhibition such as treatment with rapamycin, TGF b, lovastatin or high cell density cultures (Vadiveloo et al., 1996 ; N Rivard and J Pouyssegur, manuscript in preparation). We proposed that G 1 cyclin-dependent kinases, once activated, could initiate the degradation of p27
Kip1 by the proteasome machinery (Lavoie et al., 1996b) , thus acting as`sensor' of G 1 progression. Consistent with this proposal, cells derived from p27
Kip1 -de®cient mice are still sensitive to TGF b and rapamycin (Nakayama et al., 1996) . With such Kip1 7/7 cells now available, it would be very interesting to determine as well their sensitivity to cAMP.
One of the most striking observations from the present study is that 8Br-cAMP still prevents p27 Kip1 degradation in cyclin D1-transfectants in which the G 1 block has been partially released as shown by pRb hyperphosphorylation, cyclin A induction and thymidine incorporation (see Figures 7 and 8 ). If our previous hypothesis is proven to be correct, then the situation of p27
Kip1 increasing in response to cAMP represents an intriguing feature. Based on results showing that 8Br-cAMP is no longer able to block the serum-induced p27 Kip1 degradation in hamster ®broblasts deprived in protein kinase A (N Rivard and F McKenzie, personal communication), we know that cAMP exerts its eect on p27
Kip1 through PKA. Recently, PKA was shown to phosphorylate, at least in vitro, p27 Kip1 (Yin Sun, personal communication). Through either this action or the possible PKAmediated phosphorylation of some components of the proteasome, the growth signal initiating p27 Kip1 degradation should be prevented. In this regard, analysing the p27 Kip1 regulation in cells for which cAMP is a growth promoting agent would be very informative. Accordingly, one could speculate that in Swiss 3T3 or in FRTL5 cells for example, the addition of cAMP will induce the degradation of p27 Kip1 .
In conclusion, this report has demonstrated that, in addition to an elevation of p27
Kip1
, cAMP-mediated growth inhibition is triggered via a suppression of cyclin D1 induction. Interestingly, these two separate actions are complementary since both cooperate towards the inhibition of G 1 cyclin-dependent kinases. We propose that overexpression of cyclin D1 behaves as an`anti p27 Kip1 factor': generating higher amounts of cyclin D1/cdk4 complexes will allow titration of the inhibitor, thus explaining why cyclin D1 transfectants can grow with undegraded levels of p27 Kip1 . From this conclusion, we could anticipate that p27
Kip1 -de®cient ®broblasts are less, but still inhibited by cAMP, whereas a constitutive expression of cyclin D1 in these cells should totally release the inhibition. Preliminary experiments using anti-sense p27
Kip1 approach are in support of this conclusion.
Materials and methods
Cell culture and cell transfection
Cell culture The CCL39 cell line was from the American Type Culture Collection (Bethesda, USA). The CCL39-mutant derivative PS120 was selected previously (PouysseÂ gur et al., 1984) as being totally deprived in Na + /H + exchange activity, a biochemical characteristic used in our laboratory to select positive clones after co-transfection experiments with the reporter Na + /H + antiporter gene (NHE3) and the gene of interest (PageÁ s et al., 1993 (PageÁ s et al., , 1994 . Cells were cultivated in DME medium supplemented with cAMP inhibits cell growth via cyclin D17.5% FCS (Gibco, France) in a humidi®ed 5% CO 2 atmosphere. Cells were rendered quiescent by a 24 h serum deprivation treatment.
Expression vectors
The cDNA coding for the rat NHE3 isoform of the Na + /H + antiporter gene (Orlowski et al., 1992) was inserted (Fafournoux et al., 1994; Noel et al., 1996) into the pECE vector (InVitrogen). The human cyclin D1 cDNA was previously cloned (Baldin et al., 1993) into the pX vector (InVitrogen), and thus placed under the control of the heterologous CMV promoter and enhancer.
Transfection CCL39 and PS120 cells were transfected with the calcium phosphate precipitation method as previously described (PageÁ s et al., 1993 (PageÁ s et al., , 1994 . 50% con¯uent cells in 100 mm dishes were co-transfected overnight with 2 mg of the Na + H + antiporter sequence (NHE3 being used as the selector gene for both PS120 and CCL39 cells) along with 18 mg of the cyclin D1 expression vector (gift of Dr VeÂ ronique Baldin, IPBS, CNRS, Toulouse, France). For CCL39 cells that express endogenous NHE1, this exchanger was inhibited by the speci®c inhibitor HOE694 (a kind gift of Dr W Scholz, Hoescht AG, Frankfurt, Germany) which speci®cally blocks the endogenous NHE1 isoform with little interference with exogenous NHE3 (Counillon et al., 1993) . As a result, most colonies expressing a functional NHE3 protein by virtue of their resistance to intracellular acidi®cation would express cyclin D1. Stable transfectants were obtained after three to four rounds of H + suicide selection over 10 to 12 days of culture. Then clones were picked and recloned for puri®cation.
Immunoblotting Equal amounts of protein from whole cell lysates were loaded and separated through 8.5% SDS ± PAGE. Gels were then equilibrated in transfer buer (50 mM Tris-HCl, 180 mM glycine) and electrotransferred onto nitrocellulose (Amersham, France) for 2 h at 50 volts or overnight at 150 mA. Transfer quality was checked by staining with Ponceau S. Western blots were blocked for 1 h at 378C with 10% low fat milk in PBS+0.1% Triton X100 (Sigma, France) before decoration for 2 ± 3 h at room temperature (RT) with speci®c antibodies, then washed in PBS+0.1% Triton X100 (4610 min). This was sequentially followed by 1 h incubation (RT) with goat either anti-rabbit (for polyclonal Abs) or anti-mouse (for mAbs) IgG horseradish peroxidase conjugated (Sigma, France). Peroxydase activity was revealed using an enhanced chemiluminescence (ECL) kit (Amersham, France).
Antibodies source and characterization
Mouse monoclonal antibodies against pRb were purchased from Pharmingen (Clinisciences, Paris, France) and used at the 1 : 200 dilution in Western blotting experiments (WB). The previously characterized mouse monoclonal antibodies against cyclin D1 (DCS-6), cyclin D2 (DCS-3, DCS-5), cyclin D3 (DCS-22) and against p27 KIP1 (DCS-72) (Lukas et al., 1995a (Lukas et al., , 1994b Rivard et al., 1996) were generous gifts from Dr Jiri Bartek (Danish Cancer Society, Copenhagen, Denmark). Monoclonal DCS-6 and DCS-22 Abs were used at the 1 : 1000 dilution in WB; anti-cyclin D2 Abs (DCS-3 and DCS-5) were tested from 1 : 1000 to 1 : 100 dilution.
Rabbit polyclonal antibodies for cyclin D1, cyclin E, and cdk2 were from Dr VeÂ ronique Baldin (IPBS, CNRS, Toulouse, France). The polyclonal peptide antibodies were raised against respectively the recombinantly produced human cyclin D1 protein, the N-terminus part (13 aa) of the human cyclin E sequence, or the C-terminus part (11 aa) of the human cdk2 sequence. Polyclonal Ab against cyclin D1 was used at the 1 : 2000 dilution in WB and at the 1 : 250 dilution in immunoprecipitation experiments (IP). Polyclonal anti-cdk4 against the human C-terminus sequence was kindly provided by Dr Bernard Ducommun (IPBS, CNRS, Toulouse, France) and used at the 1 : 1000 dilution in WB and at the 1 : 500 dilution in IP.
Anity puri®ed anti-cyclin A antibodies (1 : 300 in WB) was a kind gift of Dr Sobczack-Thepot, HoÃ pital Necker, Paris.
Whenever available, antibodies were tested in hamster ®broblasts for their speci®city in WB and in IP by comparison with non-immune sera. We also veri®ed that anti-cyclin D1 or anti-cdk4 Abs, and anti-cyclin E or anticdk2 Abs were able to sustain kinasic activity towards respectively the exogenous substrates pRb-GST or H1 histone.
Immunoprecipitation
Cells were cultivated in 100 mm dishes until con¯uence, then rendered quiescent by serum starvation for 24 h and re-stimulated before harvesting. Cell lysis was performed by a 10 min incubation on ice with 1 ml/dish of lysis buer (150 mM NaCl, 1 mM EDTA, 40 mM Tris, pH 7.6+1% Triton X100) supplemented with protease inhibitors (0.1 mM PMSF, 1 mg/ml pepstatin, 10 mg/ml aprotinin, 10 mg/ml leupeptin) and phosphatase inhibitors (0.1 mM NaVO 4 , 20 mM para-nitro phenyl phosphate, 40 mM bglycerophosphate). Lysates were then cleared by centrifugation (10 000 g, 10 min) before a 2 h incubation at 48C with protein A-Sepharose (Sigma, France) pre-incubated for 1 h with immune sera. Each antibody having a dierent titer, a 1 : 50 to 1 : 250 dilution was used for maximal immunoprecipitation. Then, immunocomplexes were ®rst washed four times with ice-cold lysis buer, and three times with ice-cold kinase buer (20 mM PNPP, 10 mM MgCl 2 , 1 mM DTT, in 30 mM HEPES, pH 7.4), before performing the kinase assay.
Kinase assay
Kinase reaction was started by incubating the washed immunocomplexes at 308C in the presence of the corresponding in vitro substrate and of [ 32 P]ATP (Amersham France) at 20 ± 100 mM, 1 ± 5 mCi/assay. In order to get reasonable counts, higher speci®c radioactivity was used for cyclin D1-associated and cdk4 enzymatic activities. The kinasic substrates used were either histone H1 (Boehringer, Mannheim, Germany) for cyclin Eassociated and cdk2 activities, or pRb-GST for cyclin D1-associated and cdk4 activities. After 30 min, the reaction was stopped by addition of hot Laemmli's buer. Radiolabelled substrates were separated from immunocomplexes by SDS ± PAGE (10% for histone H1, 7.5% for pRb-GST), and autoradiographed, then cut out and counted. The duration time of the kinase assay was chosen after veri®cation that the incorporation of [ 32 P] on histone H1 was linear over at least 45 min.
Puri®cation of pRb-GST
pRb-GST construct in pGEX-2T was a kind gift of Dr Joan MassagueÂ (Memorial Sloan-Kettering Cancer Center, New York). Overnight cultures of JM109 were diluted 1 : 10 in fresh culture broth for 2 h then IPTG (0.1 mM) supplemented for 3 h before lysis in ice-cold TNEN buer (20 mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA, 0.5% NP40). Lysates were sonicated then cleared by centrifugation before applying them on Agarose-GSH column (Pharmacia, France) pre-equilibrated in TNEN buer. After extensive washing in TNEN buer, the pRb-GST protein was eluted with three volumes of column of 50 mM Tris, pH 8.0+10 mM glutathione, then aliquoted at 7808C. 1 mg of pRb-GST was used per assay.
cAMP inhibits cell growth via cyclin D1
DNA synthesis reinitiation
Cells were grown in 24-well dishes until con¯uence, then serum-deprived for 24 h before stimulation with mitogen for various times. All these steps were performed either in DME-Ham (1 : 1) medium (Figure 8) , or in the thymidine-poor DME medium alone for the thymidinepulse experiment (Figure 2 ) to ensure higher speci®c radioactivity. The reaction was stopped by rinsing the cells four times with 5% TCA. Then, the cells were harvested in 0.1 M NaOH, and the radioactivity incorporated in the TCA-insoluble fraction was counted by liquid scintillation.
Abbreviations 8Br-cAMP: 8 bromo-cyclic AMP; a.a.: amino acid; cAMP: cyclic adenosine mono-phosphate; CDK: cyclin-dependent kinase; CKI: cyclin-dependent kinase inhibitor; DME medium: Dulbecco's modi®ed Eagle medium; DTT: dithiothreitol; ERK: extracellularly regulated kinase; FCS: fetal calf serum; GST: glutathione S transferase; IPTG: isopropyl-thio-galactoside; MAP kinase: Mitogen-Activated Protein kinase; MEK: MAP and ERK Kinase; PAGE: polyacrylamide gel electrophoresis; PBS: phosphate buer saline; PKA: protein kinase A; PMSF: phenyl methyl sulfonyl¯uoride; PNPP: para nitro phenyl phosphate; pRb: retinoblastoma protein; SDS: sodium dodecyl sulfate.
